NASDAQ:VBIO Valion Bio, Inc. Common Stock (VBIO) Stock Price, News & Analysis $2.38 -0.10 (-4.03%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsSEC Filings About Valion Bio, Inc. Common Stock Stock (NASDAQ:VBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VBIO alerts:Sign Up Key Stats Today's Range$2.33▼$2.4850-Day Range$2.08▼$8.3152-Week Range$2.05▼$78.75Volume128,291 shsAverage Volume3.48 million shsMarket Capitalization$2.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California. Read More Valion Bio, Inc. Common Stock Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreVBIO MarketRank™: Valion Bio, Inc. Common Stock scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingValion Bio, Inc. Common Stock has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageValion Bio, Inc. Common Stock has only been the subject of 1 research reports in the past 90 days.Read more about Valion Bio, Inc. Common Stock's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Valion Bio, Inc. Common Stock is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Valion Bio, Inc. Common Stock is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioValion Bio, Inc. Common Stock has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.44% of the float of Valion Bio, Inc. Common Stock has been sold short.Short Interest Ratio / Days to CoverValion Bio, Inc. Common Stock has a short interest ratio ("days to cover") of 0.28, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Valion Bio, Inc. Common Stock has recently decreased by 88.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldValion Bio, Inc. Common Stock does not currently pay a dividend.Dividend GrowthValion Bio, Inc. Common Stock does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Valion Bio, Inc. Common Stock this week, compared to 2 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Valion Bio, Inc. Common Stock insiders have not sold or bought any company stock.Percentage Held by Insiders2.50% of the stock of Valion Bio, Inc. Common Stock is held by insiders.Percentage Held by Institutions4.25% of the stock of Valion Bio, Inc. Common Stock is held by institutions.Read more about Valion Bio, Inc. Common Stock's insider trading history. Receive VBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valion Bio, Inc. Common Stock and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VBIO Stock News HeadlinesValion Chair Jensen Outlines Focus On Entolimod Development; Stock DownOctober 6 at 3:05 PM | rttnews.comValion Bio, Inc. Common Stock (NASDAQ:VBIO) Sees Large Decline in Short InterestSeptember 27, 2026 | americanbankingnews.comThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tariff-driven supply chain shocks continue to build beneath market headlines. Parkview Capital's new Market Crash Survival Guide breaks down what's happening under the surface and how investors are positioning their retirement savings in response.October 6 at 1:00 AM | Parkview Capital Group (Ad)Valion Bio, Inc. Announces Appointment of Dean Zikria as Interim Chief Executive OfficerSeptember 25, 2026 | marketscreener.comMValion Bio, Inc.: Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing RuleSeptember 23, 2026 | finanznachrichten.deVBIO - Valion Bio, Inc.September 10, 2026 | seekingalpha.comValion Bio's Reverse Stock Split Takes Effect Today, August 31, 2026; Stock UpAugust 31, 2026 | rttnews.comValion Bio, Inc.: Valion Bio Announces Reverse Stock SplitAugust 27, 2026 | finanznachrichten.deSee More Headlines VBIO Stock Analysis - Frequently Asked Questions How have VBIO shares performed this year? Valion Bio, Inc. Common Stock's stock was trading at $36.25 at the beginning of the year. Since then, VBIO shares have decreased by 93.4% and is now trading at $2.38. How were Valion Bio, Inc. Common Stock's earnings last quarter? Valion Bio, Inc. Common Stock (NASDAQ:VBIO) issued its quarterly earnings results on Thursday, May, 14th. The company reported ($55.75) EPS for the quarter. Read the conference call transcript. When did Valion Bio, Inc. Common Stock's stock split? Valion Bio, Inc. Common Stock's stock reverse split before market open on Wednesday, August 23rd 2023.The 1-100 reverse split was announced on Wednesday, August 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Valion Bio, Inc. Common Stock? Shares of VBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Valion Bio, Inc. Common Stock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Valion Bio, Inc. Common Stock investors own include Meta Platforms (META), CrowdStrike (CRWD), Applied DNA Sciences (APDN), Bionomics (BNOX), Cameco (CCJ) and BlackRock ESG Capital Allocation Term Trust (ECAT). Company Calendar Last Earnings5/14/2026Today10/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 VBIO's financial health is in the Red zone, according to TradeSmith. VBIO has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VBIO Previous SymbolNASDAQ:TIVC CIK1787740 Webwww.tivichealth.com Phone(888)276-6888FaxN/AEmployees10Year Founded2016Profitability EPS (Trailing Twelve Months)($159.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.88 million Net MarginsN/A Pretax Margin-14,936.05% Return on Equity-193.17% Return on Assets-67.10% Debt Debt-to-Equity Ratio1.74 Current Ratio1.11 Quick Ratio0.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$166.26 per share Price / Book0.01Miscellaneous Outstanding Shares888,000Free Float866,000Market Cap$2.11 million OptionableNot Optionable Beta1.80 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:VBIO) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredThis list won't be up much longerBill Poulos and his team rebuild their Top 10 Stocks to Buy This Quarter report from scratch every quarter, pu...Profits Run | SponsoredParisian Penthouse: $650 a month (and your own chauffeur)A penthouse apartment for 650 a month in one of the ritziest neighborhoods in the city, comparable to Manhatta...International Living | SponsoredTrump Once Threatened THIS Country (Not Iran)Trump recently threatened a major economy not Iran, Canada, Mexico, or China over a new law that could hurt on...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valion Bio, Inc. Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Valion Bio, Inc. Common Stock With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
